Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, Christophe Louvet et al.|The Lancet Oncology|2021Cited by 1.3k
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThierry Conroy, Antoine Adenis, Marie‐Pierre Galais et al.|The Lancet Oncology|2014Cited by 446
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal CancerJean‐Pierre Gérard, Thierry Conroy, D. Azria et al.|Journal of Clinical Oncology|2012Cited by 431
Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancerJane Blazeby, Derek Alderson, Thierry Conroy et al.|European Journal of Cancer|2003Cited by 415
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialThierry Conroy, Christophe Borg, Florence Castan et al.|Annals of Oncology|2024Cited by 187